The investor, Atlas Special Opportunities, LLC, has received 483 Notes (including 8 Convertible Bonds issued in relation to the transaction fee) with a nominal value of €1,000 each.
NOXXON maintains an updated summary table of issued convertible bonds in the Investors’ section of its website.
The characteristics, terms, conditions and dilutive potential of the financing may be found in the Annex to the press release published on April 23, 2020 available on the company’s website.
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients and further studies are being planned in these indications. In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
Noxxon Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin
Telefon: +49 30 72 62 47 0
Telefax: +49 (30) 726247-225
https://www.noxxon.com/
NewCap
Telefon: +33 (1) 447100-15
E-Mail: arouille@newcap.fr
Chief Executive Officer
Telefon: +49 (30) 726247101
E-Mail: amangasarian@noxxon.com
Trophic Communications
Telefon: +49 (89) 2388-7730
E-Mail: schweitzer@trophic.eu
Trophic Communications
Telefon: +49 (172) 861-8540
E-Mail: schweitzer@trophic.eu
